Screening for prevention and early diagnosis of cancer.

Wardle, Jane; Robb, Kathryn A.; Vernon, Sally W.; Waller, Jo

doi:10.1037/a0037357

Cited by 134 publications

(104 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, a survey of recipients of FP screening test results found 40% described the experience as ''very scary'' or ''the scariest time of my life'' (Schwartz et al, 2004). In general, research has shown FP cancer screening test results can impact affective (e.g., distress), cognitive (e.g., risk perception), and behavioral outcomes (e.g., participation in future cancer screening) (e.g., Brewer et al, 2007;Lin et al, 2008;McGovern et al, 2004;Slatore et al, 2014;Taylor et al, 2004;Wardle & Pope, 1992;Wardle et al, 2015).…”

Section: Introductionmentioning

confidence: 98%

Affective, cognitive and behavioral outcomes associated with a false positive ovarian cancer screening test result

2017

View full text Add to dashboard Cite

While participation in cancer screening can facilitate early detection and improved prognosis, all screening tests yield some proportion of abnormal test results which are later determined benign. These false positive (FP) results can negatively impact affective, cognitive, and behavioral outcomes. Women participating in an ovarian cancer (OC) screening program receiving an abnormal screening test result (n = 375) were matched with women receiving normal results (n = 375). Both groups completed a baseline and 1- and 4-month follow-up assessments. FP test results were clearly associated with increased cancer-specific distress and increased perceptions of OC risk with more limited evidence for increased perceived positive consequences of screening and increased intentions to participate in future OC screening. FP OC screening test results negatively impact both affective and cognitive outcomes which may serve to reduce motivation to participate in future routine screening. The development and testing of brief, timely interventions to minimize this negative impact is warranted.

show abstract

Section: Introductionmentioning

confidence: 98%

Affective, cognitive and behavioral outcomes associated with a false positive ovarian cancer screening test result

2017

View full text Add to dashboard Cite

show abstract

“…Screening and prevention efforts can reduce mortality due to cancer. Screening detects abnormalities before they are clinically apparent, thereby enabling intervention before cancer has developed or at an early stage, when treatment is most effective 4, 5. However, susceptible population groups for whom screening should be recommended have not been determined.…”

Section: Introductionmentioning

confidence: 99%

Recurrent aphthous stomatitis may be a precursor or risk factor for specific cancers: A case‐control frequency‐matched study

et al. 2018

View full text Add to dashboard Cite

BackgroundRecurrent aphthous stomatitis (RAS) is considered a prophase symptom in patients with specific cancers. This study assessed the association between RAS and subsequent onset of cancer based on a nationwide population‐based database in Taiwan.Materials and MethodsWe selected study participants from the National Health Insurance Research Database from January 2000 to December 2008. Patients in the non‐RAS cohort were matched to case study patients at a 1:1 ratio through frequency matching. All participants were followed up for at least 5 years, and those who received cancer diagnoses during follow‐up were identified.ResultsAmong 52 307 patients with and 52 304 patients without RAS, the combined hazard ratio (HR) of all subsequent cancer cases was 1.3 (95% confidence interval [CI]: 1.25‐1.35, P = 0). RAS diagnosis was associated with risk for cancers of the head and neck (aHR = 2, 95% CI: 1.8‐2.3), colon (aHR = 1.2, 95% CI: 1.1‐1.4), liver (aHR = 1.1, 95% CI: 1‐1.3), pancreas (aHR = 1.4, 95% CI: 1.1‐1.7), skin (aHR = 1.4, 95% CI: 1.2‐1.7), breast (aHR = 1.2, 95% CI: 1.1‐1.4), and prostate (aHR = 1.5, 95% CI: 1.3‐1.8), as well as hematologic cancers (aHR = 1.6, 95% CI: 1.3‐1.9). A higher risk was observed for male patients (aHR = 1.35, 95% CI: 1.28‐1.42) than for female patients (aHR = 1.25, 95% CI: 1.18‐1.31) with RAS.Conclusions RAS was associated with specific cancers. Susceptible RAS patients should be screened for specific cancers.

show abstract

“…Conventionally, people with symptoms or signs that suggest the presence of colorectal cancer or polyps are investigated by abdominal computed tomography or invasive screening tests, such as double-contrast barium enema (DCBE), flexible sigmoidoscopy (FS), or colonoscopy [13,14]. The latter technique is the most effective standard method and prevention tool in CRC screening, but the high cost and adverse events limits the diagnostic value [15,16].…”

Section: Introductionmentioning

confidence: 99%

Miniaturized Real-Time PCR on a Q3 System for Rapid KRAS Genotyping

Guarnaccia

Iemmolo

Petralia

et al. 2017

Sensors

View full text Add to dashboard Cite

Colorectal cancer (CRC) is an aggressive human malignancy with a complex genomic landscape harboring KRAS mutations. In 40%–60% of patients with CRC, constantly active KRAS proteins affect the prognosis, surgical strategy, and clinical benefit from therapy with anti-epidermal growth factor receptor (EGFR) agents. For this reason, there is a greater demand for minimally-invasive diagnostic devices to characterize the genetic pattern and prevent the acquired mechanism to drug resistance. The rapid developments in cutting-edge diagnostic techniques are expected to play a growing role in medicine and represent an attractive promise to identify potential responders to personalized medicine. Here we propose a new method to simultaneously detect the main KRAS mutations on the portable real-time PCR Q3 platform. This platform is based on hybrid silicon-plastic technology implemented in a miniaturized chip able to achieve a sample-in answer-out rapid analysis, allowing a new approach to genetic counseling and testing.

show abstract

Screening for prevention and early diagnosis of cancer.

Cited by 134 publications

References 149 publications

Affective, cognitive and behavioral outcomes associated with a false positive ovarian cancer screening test result

Affective, cognitive and behavioral outcomes associated with a false positive ovarian cancer screening test result

Recurrent aphthous stomatitis may be a precursor or risk factor for specific cancers: A case‐control frequency‐matched study

Miniaturized Real-Time PCR on a Q3 System for Rapid KRAS Genotyping

Contact Info

Product

Resources

About